TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00705471

Intervention type: BIOLOGICAL
Intervention: Infliximab
Description: None available in the protocol. This was a chart review study, therefore no Infliximab provided during the study.
Study: NCT03912727

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha-Lipoic acid plus renal replacement therapy
Description: Alpha lipoic acid (ALA) is a vitamin-like antioxidant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: renal replacement therapy
Description: standard renal replacement therapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: renal replacement therapy
Description: standard renal replacement therapy
Study: NCT04362917

Intervention type: OTHER
Intervention: There is no intervention
Description: There is no intervention
Study: NCT02704858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perillyl alcohol
Description: Intranasal administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perillyl alcohol
Description: Intranasal administration
Study: NCT04362917

Intervention type: OTHER
Intervention: There is no intervention
Description: There is no intervention

Intervention type: OTHER
Intervention: There is no intervention
Description: There is no intervention
Study: NCT01492452

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: standardized guidelines for nursing
Description: Information was provided regarding the preoperative preparation of the child, the same conditions and in the postoperative period, as well as information relating to housing and food for the parents. The conventional orientation took about 15 minutes.
Study: NCT04050111

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stromal-vascular fraction
Description: Concentrate of stromal-vascular fraction of cells derived from autologous adipose tissue
Study: NCT02354872

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Reduction Counseling
Description: We will deliver BR in 10 (10-15 minute) sessions over a 52-week period, with an in-person session at Visit 1 followed by nine phone counseling sessions. Sessions are front-loaded to enhance acquisition of new behaviors. BR Counseling will emphasize the development of smoking control skills via feasible, specific, and graded assignments of smoking reduction activities that will be tracked over time. BR will also emphasize competence and self-efficacy, both which will be directly linked to the practice of smoking reduction skills and success in smoking control. The health counselor will provide rationales for the reduction intervention, why reduction (e.g., eliminating smoking contexts) should help the smoker, and provide the participant with specific exercises and goals. The health counselor will explicitly address pragmatic issues such as work contexts, smoking policies, and habits that interfere with smoking reduction efforts.
Study: NCT03319160

Intervention type: DEVICE
Intervention: Wearable Cardioverter Defibrillator
Description: A non-invasive wearable cardioverter defibrillator detects and treats VT/VF without the need for bystander intervention
Study: NCT03700762

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound gray-scale ratio
Description: RADinfo radiograph reading system was used to measure the gray-scales of PTMC, NG, and thyroid tissues at the same gain level, the UGSR values of the PTMC, NG, and thyroid tissue were calculated.
Study: NCT03412331

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonic
Description: Cavitron® BOBCAT® Pro, Dentsply International, USA

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonic
Description: Cavitron® BOBCAT® Pro, Dentsply International, USA

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hand Instruments
Description: Gracey, SG 5/6, 7/8, 11/12, 13/14, Hu-Friedy Ins. Co., USA
Study: NCT02304224

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eye masks
Description: eye masks from 21:00 to 6:00 each night during admission
Study: NCT03688412

Intervention type: DEVICE
Intervention: Cook lead extraction devices
Description: The Cook lead extraction devices are mechanical devices that encompass a full variety of devices required for percutaneous removal of CIED leads, indwelling catheters and foreign objects.
Study: NCT04507932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI
Description: Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of inflammatory bowel disease by PET/CT.
Study: NCT03450707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiamine 500 mg IV
Description: Thiamine hydrochloride (vitamin B1) 500mg IV will be given every 12 hours for 5 doses in the experimental arm.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100mL of intravenous normal saline will be given every 12hours for 5 doses in the placebo arm
Study: NCT01127750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTY720
Study: NCT02635464

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hUC-MSCs+Injectable collagen scaffold+CABG
Description: Patients underwent Coronary Artery Bypass Surgery (CABG) with 10\^8 allogeneic human umbilical cord mesenchymal stem cells (hUC-MSCs) in collagen scaffold injecting in the infarct region.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: hUC-MSCs+CABG
Description: Patients underwent Coronary Artery Bypass Surgery (CABG) with 10\^8 allogeneic human umbilical cord mesenchymal stem cells (hUC-MSCs) injecting in the infarct region.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG
Description: Patients underwent CABG alone.
Study: NCT00151814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil
Description: Children less than 6 years old: oral suspension or tablets equal to 0.3 mg/kg; 20 mg or 40 mg tablets for older children depending on weight.
Study: NCT02644707

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-selenomethionine
Description: The group will be randomized to receive organic selenium in the form of L-selenomethionine at the dose of 200mcg daily (intervention group) for 6 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The group will be randomized to receive placebo (control group) for 6 months
Study: NCT03532997

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ELOS
Description: The investigators aim to introduce patients with advanced cancer to supportive care resources, including specialty palliative care, through a novel web-based application called ELOS (stands for extra layer of support) in a prospective cohort study.
Study: NCT02927379

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline plus dexmetedomidine in two divided doses i.e. 20 ml is administered on each side of incision

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline plus ketamine in two divided doses i.e. 20 ml is administered on each side of incision

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline only in two divided doses i.e. 20 ml is administered on each side of incision
Study: NCT01895673

Intervention type: OTHER
Intervention: Gadolinium
Description: All patients will undergo PET-MRI additional to the PET-CT they routinely undergo. All patients will be administered Gadolinium for the PET-MRI scan. This is an extra intervention than they would normally undergo.
Study: NCT01488097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sebelipase alfa
Description: Sebelipase alfa is a recombinant human lysosomal acid lipase.
Study: NCT04407910

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AIRFLOW® Master device +Opalescence Xtra Boost.
Description: Prophylaxis techniques for pre-bleaching treatment

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AIRFLOW® Master device +Opalescence Xtra Boost.
Description: Prophylaxis techniques for pre-bleaching treatment

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: rubber-cup+Opalescence Xtra Boost.
Description: Prophylaxis techniques for pre-bleaching treatment

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: rubber-cup+Opalescence Xtra Boost.
Description: Prophylaxis techniques for pre-bleaching treatment
Study: NCT03999411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicoderm C-Q Transdermal Product
Description: 6 weeks of GlaxoSmithKline Nicoderm CQ (NRT)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicoderm C-Q Transdermal Product
Description: 6 weeks of GlaxoSmithKline Nicoderm CQ (NRT)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicoderm C-Q Transdermal Product
Description: 6 weeks of GlaxoSmithKline Nicoderm CQ (NRT)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence to Antiretroviral Therapy Counseling
Description: Brief counseling on adhering to antiretroviral therapy with self-help materials.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adherence to Antiretroviral Therapy Counseling
Description: Brief counseling on adhering to antiretroviral therapy with self-help materials.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Adherence to Antiretroviral Therapy Counseling
Description: Brief counseling on adhering to antiretroviral therapy with self-help materials.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Smoking Cessation Counseling
Description: One time face-to-face smoking cessation counseling and 2 follow-up phone calls.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Smoking Cessation Counseling
Description: One time face-to-face smoking cessation counseling and 2 follow-up phone calls.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Crave-to-Quit app
Description: Evidence-based mindfulness smoking cessation smartphone app (Crave-to-Quit) adapted from an in-person mindfulness training relapse prevention smoking cessation intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Crave-to-Quit app
Description: Evidence-based mindfulness smoking cessation smartphone app (Crave-to-Quit) adapted from an in-person mindfulness training relapse prevention smoking cessation intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: vDOT emocha app
Description: Video Directly Observed Therapy (vDOT) smartphone app (emocha) that allows participants to take a video of themselves taking medication to ensure adherence.
Study: NCT01767376

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix®
Description: One dose administered intramuscularly (IM) in the deltoid of the right arm (in Co-ad Group) and left arm (in TdapACWY and ACWYTdap Groups).
Study: NCT03846310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant
Description: Etrumadenant is an A2aR and A2bR antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant
Description: Etrumadenant is an A2aR and A2bR antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant
Description: Etrumadenant is an A2aR and A2bR antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Zimberelimab is a fully human anti-PD-1 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Zimberelimab is a fully human anti-PD-1 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin administered as part of standard chemotherapy regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin administered as part of standard chemotherapy regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin administered as part of standard chemotherapy regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin administered as part of standard chemotherapy regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed administered as part of standard chemotherapy regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed administered as part of standard chemotherapy regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed administered as part of standard chemotherapy regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed administered as part of standard chemotherapy regimen
Study: NCT03412331

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hand Instruments
Description: Gracey, SG 5/6, 7/8, 11/12, 13/14, Hu-Friedy Ins. Co., USA

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LED Source
Description: LED source (625-635 nm wavelength) (FotoSan®, CMS Dental, Denmark)
Study: NCT00797082

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI = Myocardial Perfusion Stress

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MPS
Description: MPS = Myocardial Perfusion Scintigraphy
Study: NCT03976427

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Imagery
Description: The guided imagery exercise asks participants to think about positive associations with healthy foods and imagine their future healthy selves.
Study: NCT01263548

Intervention type: DRUG
Intervention: lisdexamfetamine dimesylate
Description: Dosage form: Capsules; Dosage strength: 30-70mg/day, flexible dosing; Duration: 4 weeks
Study: NCT00699010

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acurox 5/30mg taken first
Description: followed by oxycodone 5mg with 48 hour washout

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone 5mg taken first
Description: followed by Acurox 5/30mg with 48 hour washout
Study: NCT03557307

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab subcutaneous injection
Study: NCT02416349

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory Muscles Stretching
Description: Respiratory Muscles Stretching The stretching will occur throughout the expiratory phase to allow respiratory muscles to reach their maximal length, and two sets with 10 consecutive incursions will be use for each stretching pattern with an interval of 30 seconds between series.~Pattern 1: Neck stretching Pattern 2: Upper chest stretching Pattern 3:Pectoralis major stretching Pattern 4:Lateral chest stretching

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Control Group - all volunteers will be positioned at rest in a comfortable in a chair during 20 minutes.
Study: NCT03846310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a humanized anti-PD-1 monoclonal antibody
Study: NCT03153085

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TBI-1401(HF10)
Description: 1x10\^7 TCID50/mL TBI-1401(HF10) (for a total of 6 injections; the first 4 injections at 1-week intervals; the remaining 2 injections at 3-week intervals).~Following combination therapy, patients may continue to receive the 1x10\^7 TCID50/mL TBI-1401(HF10) alone for up to an additional 13 injections (total of 19 injections = 1 year) if eligible for administration.
Study: NCT02354872

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5Rs Motivation Counseling
Description: The 5Rs Motivation Counseling will be delivered in four (10-15 min) sessions over a 52-week period. Participants in the on condition will receive three brief phone sessions over the year to prompt processing of motives for smoking reduction or cessation. The health counselor and smoker will discuss: 1) Relevance of smoking to the individual; 2) Risks of continued heavy smoking; 3) Rewards of quitting and significant reduction; and 4) Roadblocks to success; and will do so on a 5) Repeated basis. The discussion will follow the general principles of MI: counselors will use strategies that are nonauthoritarian, nonconfrontational, supportive, and use open-ended questions.
Study: NCT03153085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 3 mg/kg ipilimumab (for a total of 4 intravenous infusions, each administered at 3-week intervals).
Study: NCT02354872

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5Rs Motivation Counseling
Description: The 5Rs Motivation Counseling will be delivered in four (10-15 min) sessions over a 52-week period. Participants in the on condition will receive three brief phone sessions over the year to prompt processing of motives for smoking reduction or cessation. The health counselor and smoker will discuss: 1) Relevance of smoking to the individual; 2) Risks of continued heavy smoking; 3) Rewards of quitting and significant reduction; and 4) Roadblocks to success; and will do so on a 5) Repeated basis. The discussion will follow the general principles of MI: counselors will use strategies that are nonauthoritarian, nonconfrontational, supportive, and use open-ended questions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5Rs Motivation Counseling
Description: The 5Rs Motivation Counseling will be delivered in four (10-15 min) sessions over a 52-week period. Participants in the on condition will receive three brief phone sessions over the year to prompt processing of motives for smoking reduction or cessation. The health counselor and smoker will discuss: 1) Relevance of smoking to the individual; 2) Risks of continued heavy smoking; 3) Rewards of quitting and significant reduction; and 4) Roadblocks to success; and will do so on a 5) Repeated basis. The discussion will follow the general principles of MI: counselors will use strategies that are nonauthoritarian, nonconfrontational, supportive, and use open-ended questions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5Rs Motivation Counseling
Description: The 5Rs Motivation Counseling will be delivered in four (10-15 min) sessions over a 52-week period. Participants in the on condition will receive three brief phone sessions over the year to prompt processing of motives for smoking reduction or cessation. The health counselor and smoker will discuss: 1) Relevance of smoking to the individual; 2) Risks of continued heavy smoking; 3) Rewards of quitting and significant reduction; and 4) Roadblocks to success; and will do so on a 5) Repeated basis. The discussion will follow the general principles of MI: counselors will use strategies that are nonauthoritarian, nonconfrontational, supportive, and use open-ended questions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5Rs Motivation Counseling
Description: The 5Rs Motivation Counseling will be delivered in four (10-15 min) sessions over a 52-week period. Participants in the on condition will receive three brief phone sessions over the year to prompt processing of motives for smoking reduction or cessation. The health counselor and smoker will discuss: 1) Relevance of smoking to the individual; 2) Risks of continued heavy smoking; 3) Rewards of quitting and significant reduction; and 4) Roadblocks to success; and will do so on a 5) Repeated basis. The discussion will follow the general principles of MI: counselors will use strategies that are nonauthoritarian, nonconfrontational, supportive, and use open-ended questions.
Study: NCT02046811

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient activation and education (PAE)
Description: Text messaging and web-based tutorials for a 12-month duration (a website and smartphone interface)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAE plus physician activation (PAE + MD)
Description: Text messaging and web-based tutorials for a 12-month duration (a website and smartphone interface), physician activation/educational materials about: (1) survivors' increased skin cancer risk; (2) the benefits of and the skills needed to conduct full-body skin exams; and (3) the importance of recommending routine SSE to patients

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAE physician activation, plus teledermoscopy (PAE +MD +TD)
Description: Text messaging and web-based tutorials for a 12-month duration (a website and smartphone interface), physician activation/educational materials about: (1) survivors' increased skin cancer risk; (2) the benefits of and the skills needed to conduct full-body skin exams; and (3) the importance of recommending routine SSE to patients, and participant receipt of a dermoscopic lens
Study: NCT03894644

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation technology
Description: The intervention involves three consecutive sessions of the PeriopSim™ Instrument Trainer, followed by two consecutive sessions of the PeriopSim™ for Burr Hole Surgery (https://periopsim.com).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simulation technology
Description: The intervention involves three consecutive sessions of the PeriopSim™ Instrument Trainer, followed by two consecutive sessions of the PeriopSim™ for Burr Hole Surgery (https://periopsim.com).
Study: NCT04015973

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High energy diet
Description: An overfeeding regime of 135% required energy intake per day, set from baseline energy requirements consisting of high (saturated) fat snacks, added to the usual diet, supervised by a dietitian.
Study: NCT02952469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (68Ga)PSMA-HBED-CC
Description: Experimental radiotracer for imaging prostate cancer
Study: NCT03321149

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RiseTx
Description: Participants were given access to the RiseTx application, as well as given a Jawbone, a wrist-worn device that can assess activity patterns throughout the day and provide sensory alerts to stand after prolonged sitting (i.e., ≥30 minutes of sedentary time). The intervention consisted of five phases following initial data collection that comprised of self-regulatory strategies to reduce sitting time and self-monitoring of step counts.